CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

Albach FN, Rehm MC, Hütter-Krönke ML, Le TH, Giezen JM, Torgutalp M, Sattler A, Minopoulou I, Biesen R, Wiebe E, Casteleyn V, Witte T, Furth C, Zernicke J, Nuesch Germano M, Verhagen J, Wilhelm A, Dzamukova M, Engel K, Schallenberg S, Kannt A, Ziegler N, Fehringer M, Schneider U, Unterwalder N, Beling M, Pfeil A, Phithak E, Krusche M, Penack O, Alexander T, Stenzel W, Wuhrer M, Movassaghi K, Dörner T, Latz E, Vogl T, Busse A, Schett G, Scherer HU, Toes REM, Kleyer A, Keller U, Bullinger L, Simon D, Krönke G

Open source

DOI: 10.1038/s41591-026-04603-3
Published: 2026 Aug 27
Container: Nature medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04603-3,
  title = {CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.},
  author = {Albach FN and Rehm MC and Hütter-Krönke ML and Le TH and Giezen JM and Torgutalp M and Sattler A and Minopoulou I and Biesen R and Wiebe E and Casteleyn V and Witte T and Furth C and Zernicke J and Nuesch Germano M and Verhagen J and Wilhelm A and Dzamukova M and Engel K and Schallenberg S and Kannt A and Ziegler N and Fehringer M and Schneider U and Unterwalder N and Beling M and Pfeil A and Phithak E and Krusche M and Penack O and Alexander T and Stenzel W and Wuhrer M and Movassaghi K and Dörner T and Latz E and Vogl T and Busse A and Schett G and Scherer HU and Toes REM and Kleyer A and Keller U and Bullinger L and Simon D and Krönke G},
  year = {2026},
  journal = {Nature medicine},
  doi = {10.1038/s41591-026-04603-3},
  url = {https://doi.org/10.1038/s41591-026-04603-3}
}

RIS

TY  - JOUR
TI  - CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.
AU  - Albach FN
AU  - Rehm MC
AU  - Hütter-Krönke ML
AU  - Le TH
AU  - Giezen JM
AU  - Torgutalp M
AU  - Sattler A
AU  - Minopoulou I
AU  - Biesen R
AU  - Wiebe E
AU  - Casteleyn V
AU  - Witte T
AU  - Furth C
AU  - Zernicke J
AU  - Nuesch Germano M
AU  - Verhagen J
AU  - Wilhelm A
AU  - Dzamukova M
AU  - Engel K
AU  - Schallenberg S
AU  - Kannt A
AU  - Ziegler N
AU  - Fehringer M
AU  - Schneider U
AU  - Unterwalder N
AU  - Beling M
AU  - Pfeil A
AU  - Phithak E
AU  - Krusche M
AU  - Penack O
AU  - Alexander T
AU  - Stenzel W
AU  - Wuhrer M
AU  - Movassaghi K
AU  - Dörner T
AU  - Latz E
AU  - Vogl T
AU  - Busse A
AU  - Schett G
AU  - Scherer HU
AU  - Toes REM
AU  - Kleyer A
AU  - Keller U
AU  - Bullinger L
AU  - Simon D
AU  - Krönke G
PY  - 2026
JO  - Nature medicine
DO  - 10.1038/s41591-026-04603-3
UR  - https://doi.org/10.1038/s41591-026-04603-3
ER  -

APA

FN, A., MC, R., ML, H., TH, L., JM, G., M, T., A, S., I, M., R, B., E, W., V, C., T, W., C, F., J, Z., M, N. G., J, V., A, W., M, D., K, E., S, S., A, K., N, Z., M, F., U, S., N, U., M, B., A, P., E, P., M, K., O, P., T, A., W, S., M, W., K, M., T, D., E, L., T, V., A, B., G, S., HU, S., REM, T., A, K., U, K., L, B., D, S., & G, K. (2026). CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.. Nature medicine. https://doi.org/10.1038/s41591-026-04603-3

Source records

pubmed · retrieved 2026-09-26T03:31:08.529Z